Nimodipine
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
Nimodipine: From Cerebral Vasospasm to Homozygous Familial Hypercholesterolemia
One-Sentence Summary
Nimodipine is a dihydropyridine calcium channel blocker classically used to prevent cerebral vasospasm following subarachnoid hemorrhage. The TxGNN model predicts it may be effective for Homozygous Familial Hypercholesterolemia (HoFH), but this prediction is currently unsupported by any clinical trials or published literature — it is a pure model-driven signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in evidence pack (no TW/US license records; drug is not currently marketed in this jurisdiction) |
| Predicted New Indication | Homozygous Familial Hypercholesterolemia |
| TxGNN Prediction Score | 99.29% |
| Evidence Level | L5 (model prediction only) |
| US Market Status | 未上市 (Not marketed) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in this evidence pack (original_moa: [Data Gap]). Based on general pharmacological knowledge, nimodipine is a highly brain-selective L-type calcium channel blocker, clinically used to reduce cerebral vasospasm after subarachnoid hemorrhage.
Homozygous Familial Hypercholesterolemia is caused by dysfunction in the LDLR/APOB/PCSK9 pathway, which impairs LDL cholesterol clearance. There is no known mechanistic overlap between vascular smooth-muscle calcium channel blockade and LDL receptor-mediated cholesterol metabolism.
The TxGNN score for this candidate is high (99.29%), but with zero supporting clinical trials, zero literature records, and no plausible mechanistic bridge identified from available data, this should be treated as a pure knowledge-graph association rather than a biologically grounded hypothesis.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests solely on a TxGNN model score (L5) with no clinical trials, no literature, and no identifiable mechanistic link between nimodipine’s calcium-channel activity and HoFH’s lipid-metabolism pathology. The drug is also not currently marketed in this jurisdiction, so there is no existing regulatory or safety baseline to build on.
To proceed, the following is needed:
- TFDA/US package insert data (key warnings, contraindications) — currently blocking (DG001)
- Confirmed mechanism of action from DrugBank or primary literature (DG002)
- Preclinical or mechanistic studies linking calcium channel blockade to LDL receptor pathway or lipid metabolism
- At minimum, case reports or observational data before considering any further evaluation stage
Note: A second TxGNN candidate, nephrogenic syndrome of inappropriate antidiuresis (score 99.05%), is also flagged in this evidence pack with the same L5/Hold status and no supporting evidence — not detailed here per report scope, but subject to the same data gaps.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.